Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib

European Journal of Surgical Oncology

Volumn 39, Issue 2, 2013, Pages 150-155

  Tielen, R ^a   Verhoef, C ^b   Van Coevorden, F ^c   Gelderblom, H ^d   Sleijfer, S ^b   Hartgrink, H H ^d   Bonenkamp, J J ^a   Van Der Graaf, W T A ^a   De Wilt, J H W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gastrointestinal stromal tumour; Imatinib; Surgery

Indexed keywords

IMATINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; DUODENUM RESECTION; FEMALE; GASTRECTOMY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OVERALL SURVIVAL; PANCREAS RESECTION; PARTIAL RECTUM RESECTION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTOSIGMOID RESECTION; RECTUM ABDOMINOPERINEAL RESECTION; RETROSPECTIVE STUDY; SARCOMA; SMALL INTESTINE RESECTION; SPLENECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRECTOMY; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NETHERLANDS; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872154719     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2012.09.004     Document Type: Article

References (30)

1. C.D. Fletcher, J.J. Berman, and C. Corless Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 5 2002 May 459 465 (Pubitemid 34747864)
2. H. Joensuu, and L.G. Kindblom Gastrointestinal stromal tumors-A review Acta Orthop Scand Suppl 75 311 2004 Apr 62 71
3. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis Virchows Arch 438 1 2001 Jan 1 12 (Pubitemid 32128184)
4. S. Hirota, K. Isozaki, and Y. Moriyama Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 5350 1998 Jan 23 577 580 (Pubitemid 28067289)
5. S. Hirota, A. Ohashi, and T. Nishida Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors Gastroenterology 125 3 2003 Sep 660 667 (Pubitemid 37070684)
6. M.C. Heinrich, C.L. Corless, and A. Duensing PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 5607 2003 Jan 31 708 710 (Pubitemid 36159485)
7. R.P. DeMatteo, J.J. Lewis, D. Leung, S.S. Mudan, J.M. Woodruff, and M.F. Brennan Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 1 2000 Jan 51 58 (Pubitemid 30043939)
8. R.P. Dematteo, M.C. Heinrich, W.M. El-Rifai, and G. Demetri Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 5 2002 May 466 477 (Pubitemid 34747865)
9. E.H. Ng, R.E. Pollock, M.F. Munsell, E.N. Atkinson, and M.M. Romsdahl Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging Ann Surg 215 1 1992 Jan 68 77
10. C. Langer, B. Gunawan, P. Schuler, W. Huber, L. Fuzesi, and H. Becker Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours Br J Surg 90 3 2003 Mar 332 339 (Pubitemid 36324113)
11. P. Hohenberger, U. Ronellenfitsch, and O. Oladeji Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour Br J Surg 97 12 2010 Dec 1854 1859
12. H. Joensuu, P.J. Roberts, and M. Sarlomo-Rikala Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 14 2001 Apr 5 1052 1056 (Pubitemid 32267975)
13. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 2002 Aug 15 472 480 (Pubitemid 34879334)
14. A.T. van Oosterom, I. Judson, and J. Verweij Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 9291 2001 Oct 27 1421 1423 (Pubitemid 33055745)
15. J. Verweij, P.G. Casali, and J. Zalcberg Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 9440 2004 Sep 25-Oct 1 1127 1134 (Pubitemid 39296599)
16. C.R. Antonescu, P. Besmer, and T. Guo Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation Clin Cancer Res 11 11 2005 Jun 1 4182 4190 (Pubitemid 40791584)
17. B.L. Eisenberg, J. Harris, and C.D. Blanke Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665 J Surg Oncol 99 1 2009 Jan 1 42 47
18. M. Fiore, E. Palassini, and E. Fumagalli Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST) Eur J Surg Oncol 35 7 2009 Jul 739 745
19. A. Mearadji, M.A. den Bakker, and A.N. van Geel Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis Anticancer Drugs 19 6 2008 Jul 607 612
20. R.H. Andtbacka, C.S. Ng, and C.L. Scaife Surgical resection of gastrointestinal stromal tumors after treatment with imatinib Ann Surg Oncol 14 1 2007 Jan 14 24 (Pubitemid 44954266)
21. C.P. Raut, M. Posner, and J. Desai Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors J Clin Oncol 24 15 2006 May 20 2325 2331 (Pubitemid 46630664)
22. A. Blesius, P.A. Cassier, and F. Bertucci Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial BMC Cancer 11 1 2011 Feb 15 72
23. F. Duffaud, and P. Therasse New guidelines to evaluate the response to treatment in solid tumors Bull Cancer 87 12 2000 Dec 881 886 (Pubitemid 32094649)
24. P.J. Roberts, and B. Eisenberg Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease Eur J Cancer 38 Suppl. 5 2002 Sep S37 S38
25. R.P. Dematteo, K.V. Ballman, and C.R. Antonescu Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 9669 2009 Mar 28 1097 1104
26. H. Choi, C. Charnsangavej, and S. de Castro Faria CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings AJR Am J Roentgenol 183 6 2004 Dec 1619 1628 (Pubitemid 44210530)
27. R.S. Benjamin, H. Choi, and H.A. Macapinlac We should desist using RECIST, at least in GIST J Clin Oncol 25 13 2007 May 1 1760 1764 (Pubitemid 46797958)
28. H. Choi Response evaluation of gastrointestinal stromal tumors Oncologist 13 Suppl. 2 2008 4 7
29. A.D. Van den Abbeele The lessons of GIST-PET and PET/CT: a new paradigm for imaging Oncologist 13 Suppl. 2 2008 8 13
30. Joensuu H, Eriksson M, Hatrmann J, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). ASCO meeting abstracts. 2011 June 23, vol. 29(Suppl. 18): LBA1; 2011.